Enanta Pharmaceuticals, Inc.

How big is Enanta Pharmaceuticals, Inc.?

As of Jun 18, Enanta Pharmaceuticals, Inc. has a market capitalization of 150.70 million, with net sales of 64.47 million and a net loss of 96.41 million over the latest four quarters. Shareholder's funds are 128.81 million, and total assets amount to 390.80 million.

As of Jun 18, Enanta Pharmaceuticals, Inc. has a market capitalization of 150.70 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 64.47 million for the latest four quarters, while the net profit for the same period was a loss of 96.41 million.<BR><BR>As of Sep 24, the balance sheet shows shareholder's funds of 128.81 million and total assets amounting to 390.80 million.

What does Enanta Pharmaceuticals, Inc. do?

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases. As of March 2025, it reported net sales of $15 million and a net loss of $23 million, with a market cap of $150.70 million.

Overview: <BR>Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company in the Pharmaceuticals & Biotechnology industry, specializing in small molecule drugs for viral infections and liver diseases.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 15 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 150.70 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.36 <BR>Return on Equity: -103.08% <BR>Price to Book: 1.61 <BR><BR>Contact Details: <BR>Address: 500 Arsenal St, WATERTOWN MA: 02472-2806 <BR>Tel: ['1 617 6070800', '1 617 6070710'] <BR>Fax: 1 617 6070530 <BR>Website: https://www.enanta.com/

Should I buy, sell or hold Enanta Pharmaceuticals, Inc.?

Who are in the management team of Enanta Pharmaceuticals, Inc.?

As of March 2022, the management team of Enanta Pharmaceuticals, Inc. includes Dr. Bruce Carter (Independent Non-Executive Chairman), Dr. Jay Luly (President and CEO), and several Independent Directors: Mr. Mark Foletta, Dr. George Golumbeski, Ms. Kristine Peterson, and Dr. Lesley Russell. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Enanta Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Bruce Carter, who serves as the Independent Non-Executive Chairman of the Board.<BR>- Dr. Jay Luly, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Mark Foletta, an Independent Director.<BR>- Dr. George Golumbeski, an Independent Director.<BR>- Ms. Kristine Peterson, an Independent Director.<BR>- Dr. Lesley Russell, an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Enanta Pharmaceuticals, Inc. overvalued or undervalued?

As of November 25, 2020, Enanta Pharmaceuticals, Inc. is considered overvalued and risky due to its negative P/E ratio, poor returns on capital, and underperformance relative to peers, with a 1-year return of -31.17% compared to the S&P 500's 17.14%.

As of 25 November 2020, the valuation grade for Enanta Pharmaceuticals, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its financial metrics, particularly given its negative P/E ratio and poor returns on capital, with a Price to Book Value of 1.71, EV to Sales of 1.95, and a troubling ROCE of -170.84%. <BR><BR>In comparison to peers, Enanta's EV to EBITDA stands at -1.27, while Y-mAbs Therapeutics, Inc. has a significantly higher EV to EBITDA of -12.49, and scPharmaceuticals, Inc. at -4.64, highlighting that Enanta is underperforming relative to its industry. The stock's performance has been lackluster, with a 1Y return of -31.17% compared to the S&P 500's 17.14%, reinforcing the notion that the stock is overvalued in the current market context.

Is Enanta Pharmaceuticals, Inc. technically bullish or bearish?

As of September 10, 2025, Enanta Pharmaceuticals has a mildly bullish technical trend, with mixed signals across indicators, underperforming the S&P 500 recently but outperforming it year-to-date.

As of 10 September 2025, the technical trend for Enanta Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a mildly bullish stance. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly outlook and a bearish monthly outlook. The KST is bullish on a weekly basis but bearish monthly, and Dow Theory presents a mildly bearish weekly view alongside a mildly bullish monthly perspective. The OBV is mildly bearish weekly but mildly bullish monthly.<BR><BR>In terms of performance, Enanta Pharmaceuticals has underperformed relative to the S&P 500 over the past week and month, with returns of -9.47% and -4.04% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has outperformed the benchmark with a return of 36.35% compared to the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals across various indicators.